Medications for Cervical Cancer
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Cervical Cancer.
Found 4 Approved Drugs for Cervical Cancer
Bevacizumab
Brand Names
Zirabev, Jobevne, Avzivi tnjn, Avastin, MVASI, Avzivi, Vegzelma, Alymsys
Bevacizumab
Brand Names
Zirabev, Jobevne, Avzivi tnjn, Avastin, MVASI, Avzivi, Vegzelma, Alymsys
Form: Injection
Method of administration: Intravenous, Intravascular
FDA approval date: February 26, 2004
Classification: Vascular Endothelial Growth Factor Inhibitor
MVASI is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment.
Pembrolizumab
Brand Names
Keytruda QLEX, Keytruda
Pembrolizumab
Brand Names
Keytruda QLEX, Keytruda
Form: Injection
Method of administration: Subcutaneous, Intravenous
FDA approval date: January 15, 2015
Classification: Programmed Death Receptor-1 Blocking Antibody
KEYTRUDA QLEX is a combination of pembrolizumab, a programmed death receptor-1 (PD-1)-blocking antibody, and berahyaluronidase alfa, an endoglycosidase, indicated: Melanoma for the treatment of adult patients with unresectable or metastatic melanoma.
Hycamtin
Generic Name
Topotecan
Hycamtin
Generic Name
Topotecan
Form: Injection, Capsule
Method of administration: Oral, Intravenous
FDA approval date: November 30, 2010
Classification: Topoisomerase Inhibitor
HYCAMTIN ® capsules are indicated for the treatment of relapsed small cell lung cancer (SCLC) in patients with a prior complete or partial response and who are at least 45 days from the end of first-line chemotherapy. HYCAMTIN capsules is a topoisomerase inhibitor indicated for treatment of patients with relapsed small cell lung cancer (SCLC). ( 1 )
Tivdak
Generic Name
Tisotumab Vedotin
Tivdak
Generic Name
Tisotumab Vedotin
Form: Injection
Method of administration: Intravenous
FDA approval date: September 20, 2021
TIVDAK ® is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. TIVDAK is a tissue factor-directed antibody and microtubule inhibitor conjugate indicated for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. ( 1 )
Showing 1-4 of 4
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances